Investing in Johnson & Johnson.
Johnson & Johnson has been a part of people's lives for 128 years and a valuable part of their investments for approximately 70 years. Founded in 1886, we listed our shares on the New York Stock Exchange for public investors in 1944.
During our history, we have built the most comprehensive base of health care businesses in the world, generating approximately 70 percent of our revenues from No. 1 or No. 2 global leadership positions in our respective markets.
Our consistent performance has enabled us to deliver an exceptional track record of growth that few, if any, companies can claim: 30 consecutive years of adjusted earnings increases; and 52 consecutive years of dividend increases. Over the last 10 years, Johnson & Johnson stock generated a 8.9 percent total return for investors compared to a 7.4 percent total return for the S&P 500.(1)
October 20, 2014
IMBRUVICA® (ibrutinib) Supplemental New Drug Application Submitted to the U.S. FDA for Waldenström's macroglobulinemia
October 17, 2014
European Commission Approves IMBRUVICATM in Two Forms of Blood Cancer
October 16, 2014
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2014
October 14, 2014 at 8:30 AM ET
Johnson & Johnson Third Quarter 2014 Earnings Meeting and Webcast
Financial Quick Links
1. Data source - Bloomberg